// App-Quantinova.ai

: Comparison of individual items of COPD Assessment Test (CAT at baseline in the EMAX and IMPACT trials

Researchers

Presenter

  • Paul Jones

Principal Investigators

  • Mark Dransfield

  • Isabelle H. Boucot

  • Edward M. Kerwin

  • David A. Lipson

  • Claus F. Vogelmeier

  • Meilan Han

  • Leif Bjermer

  • Robert A. Wise

  • François Maltais

  • Lee Tombs

  • Sally Kilbride

  • Chris Compton

  • Fernando Martinez

Medical Centers

  • Global Specialty & Primary Care, GlaxoSmithKline, Brentford, Middlesex, United Kingdom

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • Clinical Research Institute of Southern Oregon, Medford, OR, United States.

  • Respiratory Clinical Sciences, GlaxoSmithKline and Perelman School of Medicine, University of Pennsylvania, Collegeville and Philadelphia, PA, United States of America

  • Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany,

  • Respiratory Medicine and Allergology, Lund University, Lund, Sweden,

  • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

  • Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, QC, Canada,

  • Precise Approach Ltd, contingent worker on assignment at GSK, Stockley Park West, Uxbridge, Middlesex, United Kingdom,

  • Biostatistics, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom

  • Weill Cornell Medical College, New York City, NY, United States

Locations

  • United Kingdom

  • United States

  • Germany

  • Sweden

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03034915

  • NCT02164513

Sponsors

  • N/A

Result

  • N/A